Inventor · disambiguated record
Paul S. Rennie
Also filed as: RENNIE PAUL · RENNIE PAUL S
17 granted patents·4 pending applications·273 citations·filing 2000–2022
94Inventor score
Top patents by PatentIndex Score
21 records- 0198US7732422B2TRPM-2 antisense therapyUNIV BRITISH COLUMBIA·Filed 2007·Granted Jun 8, 2010·125 cites·5 claims
- 0293US6900187B2TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modificationsUNIV BRITISH COLUMBIA·Filed 2002·Granted May 31, 2005·37 cites·11 claims
- 0392US7592323B1TRPM-2 antisense therapyUNIV BRITISH COLUMBIA·Filed 2006·Granted Sep 22, 2009·14 cites·11 claims
- 0492US7368436B2TRPM-2 antisense therapyUNIV BRITISH COLUMBIA·Filed 2001·Granted May 6, 2008·35 cites·8 claims
- 0590US9095602B2Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotidesGLEAVE MARTIN·Filed 2013·Granted Aug 4, 2015·7 cites·12 claims
- 0688US8361981B2Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotidesUNIV BRITISH COLUMBIA·Filed 2009·Granted Jan 29, 2013·4 cites·14 claims
- 0787US8173615B2TRPM-2 antisense therapyGLEAVE MARTIN·Filed 2010·Granted May 8, 2012·7 cites·4 claims
- 0883US7534773B1TRPM-2 antisense therapyUNIV BRITISH COLUMBIA·Filed 2000·Granted May 19, 2009·11 cites·12 claims
- 0982US8536149B2TRPM-2 antisense therapyGLEAVE MARTIN·Filed 2012·Granted Sep 17, 2013·3 cites·20 claims
- 1082US7196067B2Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapyUNIV BRITISH COLUMBIA·Filed 2001·Granted Mar 27, 2007·13 cites·8 claims
- 1181US7569551B2Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotidesUNIV BRITISH COLUMBIA·Filed 2001·Granted Aug 4, 2009·13 cites·42 claims
- 1280US10633338B2Binding Function 3 (BF3) site compounds as therapeutics and methods for their useUNIV BRITISH COLUMBIA·Filed 2019·Granted Apr 28, 2020·1 cites·16 claims
- 1375US9074209B2TRPM-2 antisense therapyGLEAVE MARTIN·Filed 2013·Granted Jul 7, 2015·1 cites·20 claims
- 1469US10351527B2Binding function 3 (BF3) site compounds as therapeutics and methods for their useUNIV BRITISH COLUMBIA·Filed 2015·Granted Jul 16, 2019·1 cites·24 claims
- 1565US8324280B2Treatment of prostate cancer with DDC inhibitorWAFA LATIF·Filed 2009·Granted Dec 4, 2012·1 cites·35 claims
- 1663US12017975B2Myc-Max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewithUNIV BRITISH COLUMBIA·Filed 2022·Granted Jun 25, 2024·0 cites·12 claims
- 1762US2021024464A1Binding function 3 (bf3) site compounds as therapeutics and methods for their useUNIV BRITISH COLUMBIA·Filed 2020·Application pending·0 cites
- 1854US2024150313A1Tri-substituted indole binding function 3 (bf3) compounds and methods for their useUNIV BRITISH COLUMBIA·Filed 2022·Application pending·0 cites
- 1940US2022112157A1Myc-max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewithUNIV BRITISH COLUMBIA·Filed 2019·Application pending·0 cites
- 2032US2020031848A1Ar-v7 inhibitorsHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 2119US10011573B2Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their useUNIV BRITISH COLUMBIA·Filed 2015·Granted Jul 3, 2018·0 cites·16 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →